Br J Haematol. Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies

[tetano]

Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16801. [Epub ahead of print]
Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies.


Mart?n-Moro F¹, Marquet J¹, Piris M¹, Michael BM¹, S?ez AJ¹, Corona M¹, Jim?nez C¹, Astibia B¹, Garc?a I¹, Rodr?guez E², Garc?a-Hoz C², Fort?n-Abete J³, Herrera P¹, L?pez-Jim?nez J¹.

Author information




Abstract

The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020).
This article is protected by copyright. All rights reserved.



PMID:32379921DOI:10.1111/bjh.16801